Pregled bibliografske jedinice broj: 228561
Use of Recombinant Factor VIIa (NovoSeven) in the management od postoperative bleeding in thoracic surgery patients
Use of Recombinant Factor VIIa (NovoSeven) in the management od postoperative bleeding in thoracic surgery patients // 16th Anaesthesia Symposium Alpe Adria. Book of Lectures
Maribor: Slovenian Society of Anaesthesiology and Intensive Care Medicine, 2003. (predavanje, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 228561 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Use of Recombinant Factor VIIa (NovoSeven) in the management od postoperative bleeding in thoracic surgery patients
Autori
Majerić-Kogler, Višnja ; Špiček Macan, Jasna ; Kogler, Jana ; Karadža, Vjekoslav
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
16th Anaesthesia Symposium Alpe Adria. Book of Lectures
/ - Maribor : Slovenian Society of Anaesthesiology and Intensive Care Medicine, 2003
Skup
16th Anaesthesia Symposium Alpe Adria
Mjesto i datum
Maribor, Slovenija, 09.05.2003. - 11.05.2003
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
thoracic surgery; intensive care; haemorrhage; coagulation; recombinant factor (NovoSeven)
Sažetak
Background: Thoracic surgery belongs to the group of "major surgery" where patients are frequently threatened for massive postoperative haemorrhage, which is closely related to prolonged postoperative morbidity and early patient mortality (23%). Recombinant factor VIIa induces haemostasis at the site of injury independent of the presence of FVIII and FIX by forming complexes with exposed tissue factor. Case description: We present favorable result obtained by use of rFVII in four patients in whom the life-threatening haemorrhage following the procedure of lung resection was successfully stopped. The early use of this agent in our patients contributed considerably to the maintenance of their satisfactory clinical and laboratory status and certainly prevented prolonged morbidity and possible fatal outcome of the operative treatment. Conclusion: We would like to contribute our modest clinical experience in the use of rFVII suggests it to be a safe and efficacious agent to institute and maintain hemostasis after life-threatening postoperative bleeding in thoracic surgery.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-0008 - Utjecaj liječenja akutne boli na tijek i ishod liječenja kirurških bolesnika (Majerić-Kogler, Višnja, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za plućne bolesti "Jordanovac"